+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastrointestinal Motility Drugs Market by Drug Type (Antiemetics, Antispasmodics, Laxatives), Mechanism Of Action (5-HT4 Agonists, Chloride Channel Activators, Dopamine Antagonists), Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Gastrointestinal Motility Drugs Market by Drug Type (Antiemetics, Antispasmodics, Laxatives), Mechanism Of Action (5-HT4 Agonists, Chloride Channel Activators, Dopamine Antagonists), Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
New

Gastrointestinal Motility Drugs Market by Drug Type (Antiemetics, Antispasmodics, Laxatives), Mechanism Of Action (5-HT4 Agonists, Chloride Channel Activators, Dopamine Antagonists), Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147983
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unveiling the Critical Role of Gastrointestinal Motility Drugs in Modern Healthcare Ecosystems Amidst Evolving Therapeutic and Technological Trends

Gastrointestinal motility drugs have become an essential cornerstone in addressing widespread digestive disorders that significantly impact quality of life. From chronic constipation and functional dyspepsia to more acute surgical recovery complications, the burden on patients and healthcare providers continues to intensify. Advancements in pharmacology have enabled more targeted approaches to modulating motility pathways, while evolving patient needs and expectations demand safer, more effective therapies.

Against this backdrop, a clear understanding of drug portfolios, emerging mechanisms of action, and the shifting regulatory environment is critical for stakeholders seeking to navigate this complex, highly competitive landscape. This executive summary is designed to provide a comprehensive yet concise overview of transformative shifts, tariff impacts, segmentation insights, regional dynamics, leading corporate strategies, and recommended actions. By synthesizing the latest industry developments, this document aims to equip decision-makers with the insights needed to drive innovation, optimize market approaches, and strengthen strategic positioning in the gastrointestinal motility domain.

Transformative Innovations and Emerging Trends Reshaping Gastrointestinal Motility Drug Development Across Therapeutic, Technological, and Regulatory Frontiers

In recent years, the development and commercialization of gastrointestinal motility drugs have experienced a profound transformation, propelled by novel therapeutic targets and an enhanced understanding of enteric neuroscience. Breakthroughs in biomarker identification have facilitated more precise patient stratification, enabling therapeutic regimens to be tailored according to individual physiological profiles and disease subtypes. Concurrently, the integration of digital health platforms with clinical care pathways has elevated patient monitoring and adherence, ushering in a new era of remote symptom tracking and real-time dosage adjustments.

Regulatory bodies have also adapted, instituting expedited review processes for therapies addressing high unmet medical needs, while promoting post-marketing surveillance frameworks to ensure ongoing safety and efficacy. Within this context, pharmaceutical developers are increasingly forging public-private partnerships to accelerate early-stage research and leverage artificial intelligence tools for lead optimization. As a result, the competitive landscape is shifting toward a model that prizes agility, collaboration, and patient-centric innovation, driving a redefinition of success in gastrointestinal motility therapeutics.

Assessing the Far-Reaching Implications of 2025 United States Tariff Measures on Gastrointestinal Motility Drug Supply Chains and Cost Structures

The introduction of new tariff measures in the United States in 2025 has injected fresh complexities into the global supply chains for gastrointestinal motility agents. Manufacturers reliant on imported active pharmaceutical ingredients and specialized excipients now face escalated costs and logistical challenges, compelling a strategic reconfiguration of procurement and production footprints. Many companies are evaluating the benefits of nearshoring select manufacturing operations to mitigate exposure to trade policy fluctuations, while reinforcing relationships with domestic suppliers to secure critical input materials.

Moreover, the tariff landscape has underscored the importance of cost-efficiency across distribution networks. Organizations are optimizing inventory management and exploring alternative packaging strategies to maintain competitive price points without compromising product quality. Simultaneously, collaborative efforts with logistics providers aim to bolster resilience against customs delays and imposition of additional duties. These industry-wide recalibrations reflect an increased emphasis on safeguarding both supply continuity and margin integrity in the face of evolving trade regulations.

Uncovering Critical Segmentation Insights Driving Strategic Decision Making Across Drug Types, Mechanisms, Indications, Routes, Channels, and End Users

A multidimensional segmentation framework is pivotal for comprehending the gastrointestinal motility drug market’s intricacies and guiding precise strategic choices. When examining drug types, antiemetics span subclasses such as 5-HT3 antagonists, dopamine antagonists, and NK1 antagonists, while antispasmodics divide into anticholinergics and calcium channel blockers. Laxatives encompass bulk forming, osmotic, stimulant varieties and stool softeners, and prokinetic agents range from 5-HT4 agonists and cholinergic agonists to dopamine antagonists and motilin receptor agonists. These categories serve as the foundation for identifying therapeutic strengths and competitive advantages.

Mechanism of action further refines the landscape, featuring platforms that include 5-HT4 agonists, chloride channel activators, dopamine antagonists, guanylate cyclase-C agonists, motilin receptor agonists, and NK1 antagonists. Each modality delivers distinct pharmacodynamics and safety profiles, enabling developers to align clinical benefits with patient-specific needs. From an indication standpoint, critical focus areas comprise chronic constipation, functional dyspepsia, gastroparesis, irritable bowel syndrome, and postoperative ileus, highlighting a spectrum of conditions that demand tailored therapeutic solutions.

Route of administration and distribution channel considerations reveal additional layers of strategic potential. Oral formulations dominate for outpatient therapy, while parenteral options address acute care settings. Distribution pathways stretch from hospital pharmacy environments to online platforms and retail pharmacy outlets, each offering unique access dynamics and patient engagement opportunities. Finally, end user segmentation-clinics, home care settings, and hospitals-illuminates the diverse care delivery models in which gastrointestinal motility therapies play an integral role, guiding product positioning and support services.

Navigating Regional Dynamics and Market Nuances Across the Americas, Europe Middle East and Africa and Asia Pacific to Inform Strategic Investments

Across the Americas, a robust healthcare infrastructure and advanced reimbursement systems have fostered early adoption of innovative gastrointestinal motility therapies. Clinicians in North America particularly emphasize efficacy and safety data generated through rigorous clinical trials, which bolsters confidence in novel agents. Meanwhile, Latin American markets are characterized by growing healthcare expenditures and strategic collaborations aimed at expanding access, albeit within the constraints of budgetary considerations.

In Europe, Middle East and Africa, regulatory harmonization across the European Union contrasts with diverse approval pathways in Middle Eastern and African nations. This multiplicity of systems necessitates tailored market entry strategies that account for localized pricing regulations, reimbursement policies, and distribution capabilities. Stakeholders are leveraging regional alliances and technology transfer initiatives to overcome infrastructure variability and enhance patient reach.

Asia Pacific markets present a dynamic tableau of both established and emerging economies. In regions such as Japan and Australia, stringent regulatory standards and well-defined clinical guidelines support the introduction of cutting-edge prokinetic agents. Simultaneously, rapidly developing markets in Southeast Asia and South Asia offer high-growth potential driven by rising prevalence of gastrointestinal disorders and expanding access to healthcare services. Strategic partnerships with local manufacturers and government health programs are essential to navigate complex regulatory landscapes and deliver cost-effective therapies.

Evaluating Competitive Landscapes and Corporate Strategies Shaping Leadership Positions in the Gastrointestinal Motility Drug Arena

The competitive arena for gastrointestinal motility drugs is marked by the presence of major pharmaceutical innovators and a spectrum of emerging biotech firms. Established global leaders with diverse R&D portfolios continue to invest in next-generation prokinetic and antiemetic candidates, leveraging deep pockets and extensive clinical development expertise. Concurrently, specialized companies are gaining traction by concentrating on niche mechanisms of action such as chloride channel modulation and motilin receptor agonism, aiming to address specific unmet clinical needs.

Strategic partnerships and licensing agreements have emerged as critical levers for portfolio expansion. Alliances between multinational organizations and regional biotech ventures enable accelerated clinical trials and localized expertise. Moreover, mergers and acquisitions are reshaping the market, as larger entities integrate complementary pipelines to achieve therapeutic breadth and leverage synergies in manufacturing and distribution. This landscape underscores a dual approach: broad diversification by industry titans alongside targeted innovation driven by agile newcomers.

Actionable Strategic Recommendations Empowering Industry Leaders to Navigate Disruption and Capitalize on Growth Opportunities in Gastrointestinal Motility

Industry participants seeking to capitalize on market potential should first prioritize investment in precision medicine initiatives that identify patient subpopulations most likely to benefit from specific motility mechanisms. Establishing dedicated partnerships with diagnostic firms will enable the integration of biomarkers into clinical trials and real-world studies. Additionally, companies should reinforce supply chain resilience by diversifying sourcing locations and exploring strategic near-shoring opportunities to mitigate tariff-induced cost volatility.

Another key priority is the deployment of digital engagement tools to improve patient adherence and gather real-time efficacy data. Collaborations with digital health start-ups and telemedicine platforms can yield powerful patient support programs, driving long-term outcomes and product differentiation. Simultaneously, organizations are advised to pursue region-tailored regulatory and distribution strategies, customizing market entry plans according to local pricing environments and healthcare access models. By combining agile operational frameworks with targeted innovation, industry leaders can unlock sustainable growth in an increasingly competitive arena.

Detailing Rigorous Research Methodology and Analytical Frameworks Employed to Ensure Reliable Insights into Gastrointestinal Motility Drug Markets

This report’s findings derive from a rigorous research methodology integrating both primary and secondary data sources. The primary research component encompassed in-depth interviews with key opinion leaders, clinical practitioners, regulatory experts, and supply chain managers across major markets. These conversations provided direct insight into emerging clinical needs, patient access challenges, and strategic priorities influencing both established and emerging players.

Complementing primary inputs, secondary research involved comprehensive review of peer-reviewed literature, patent filings, regulatory databases, and industry white papers. Data points were triangulated and validated through cross-referencing multiple reputable sources to ensure reliability and mitigate bias. A structured analytical framework was applied to segmentation, regional dynamics, competitive landscapes, and tariff impact assessment, enabling a cohesive synthesis of complex market drivers and strategic imperatives.

Concluding Reflections on the Future Preparedness and Strategic Imperatives Within the Evolving Gastrointestinal Motility Drug Ecosystem

In closing, the gastrointestinal motility drug space stands at an inflection point characterized by scientific breakthroughs, evolving regulatory pathways, and shifting global trade dynamics. Organizations that proactively align their R&D strategies with emerging mechanisms of action, fortify supply chain resilience against tariff uncertainties, and adopt region-specific engagement models will be best positioned to lead the next wave of innovation.

By leveraging granular segmentation insights, competitive intelligence, and robust methodological rigor, stakeholders can chart a clear course through complexity and capitalize on the significant unmet medical needs prevalent across diverse patient populations. The strategic imperatives outlined herein serve as a roadmap for sustainable success and long-term value creation in a therapeutic area that continues to gain prominence within modern healthcare ecosystems.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Antiemetics
      • 5-HT3 Antagonists
      • Dopamine Antagonists
      • NK1 Antagonists
    • Antispasmodics
      • Anticholinergics
      • Calcium Channel Blockers
    • Laxatives
      • Bulk Forming Laxatives
      • Osmotic Laxatives
      • Stimulant Laxatives
      • Stool Softeners
    • Prokinetic Agents
      • 5-HT4 Agonists
      • Cholinergic Agonists
      • Dopamine Antagonists
      • Motilin Receptor Agonists
  • Mechanism Of Action
    • 5-HT4 Agonists
    • Chloride Channel Activators
    • Dopamine Antagonists
    • Guanylate Cyclase-C Agonists
    • Motilin Receptor Agonists
    • NK1 Antagonists
  • Indication
    • Chronic Constipation
    • Functional Dyspepsia
    • Gastroparesis
    • Irritable Bowel Syndrome
    • Postoperative Ileus
  • Route Of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • Almirall, S.A.
  • AstraZeneca plc
  • Nektar Therapeutics, Inc.
  • Otsuka Pharmaceutical Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of ghrelin receptor agonists for refractory gastroparesis management
5.2. Emergence of microbiome modulation therapies addressing opioid induced constipation symptoms
5.3. Integration of digital health platforms to monitor real world gastrointestinal motility outcomes
5.4. Surge in clinical trials evaluating selective 5 HT4 receptor agonists with improved safety profiles
5.5. Expansion of personalized treatment approaches based on motility biomarker diagnostics
5.6. Growing pressure from generics and biosimilars impacting branded prokinetic drug pricing strategies
5.7. Evolving regulatory frameworks streamlining approval pathways for novel prokinetic agents
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gastrointestinal Motility Drugs Market, by Drug Type
8.1. Introduction
8.2. Antiemetics
8.2.1. 5-HT3 Antagonists
8.2.2. Dopamine Antagonists
8.2.3. NK1 Antagonists
8.3. Antispasmodics
8.3.1. Anticholinergics
8.3.2. Calcium Channel Blockers
8.4. Laxatives
8.4.1. Bulk Forming Laxatives
8.4.2. Osmotic Laxatives
8.4.3. Stimulant Laxatives
8.4.4. Stool Softeners
8.5. Prokinetic Agents
8.5.1. 5-HT4 Agonists
8.5.2. Cholinergic Agonists
8.5.3. Dopamine Antagonists
8.5.4. Motilin Receptor Agonists
9. Gastrointestinal Motility Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. 5-HT4 Agonists
9.3. Chloride Channel Activators
9.4. Dopamine Antagonists
9.5. Guanylate Cyclase-C Agonists
9.6. Motilin Receptor Agonists
9.7. NK1 Antagonists
10. Gastrointestinal Motility Drugs Market, by Indication
10.1. Introduction
10.2. Chronic Constipation
10.3. Functional Dyspepsia
10.4. Gastroparesis
10.5. Irritable Bowel Syndrome
10.6. Postoperative Ileus
11. Gastrointestinal Motility Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
12. Gastrointestinal Motility Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Gastrointestinal Motility Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Home Care Settings
13.4. Hospitals
14. Americas Gastrointestinal Motility Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Gastrointestinal Motility Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Gastrointestinal Motility Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Bausch Health Companies Inc.
17.3.3. Ironwood Pharmaceuticals, Inc.
17.3.4. Astellas Pharma Inc.
17.3.5. Takeda Pharmaceutical Company Limited
17.3.6. Johnson & Johnson
17.3.7. Almirall, S.A.
17.3.8. AstraZeneca plc
17.3.9. Nektar Therapeutics, Inc.
17.3.10. Otsuka Pharmaceutical Co., Ltd.
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. GASTROINTESTINAL MOTILITY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GASTROINTESTINAL MOTILITY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GASTROINTESTINAL MOTILITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. GASTROINTESTINAL MOTILITY DRUGS MARKET: RESEARCHAI
FIGURE 28. GASTROINTESTINAL MOTILITY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. GASTROINTESTINAL MOTILITY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. GASTROINTESTINAL MOTILITY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GASTROINTESTINAL MOTILITY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY BULK FORMING LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY BULK FORMING LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY 5-HT4 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY 5-HT4 AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CHOLINERGIC AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CHOLINERGIC AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY 5-HT4 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY 5-HT4 AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CHLORIDE CHANNEL ACTIVATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CHLORIDE CHANNEL ACTIVATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY GUANYLATE CYCLASE-C AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY GUANYLATE CYCLASE-C AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CHRONIC CONSTIPATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CHRONIC CONSTIPATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY GASTROPARESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY POSTOPERATIVE ILEUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY POSTOPERATIVE ILEUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 145. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 146. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 147. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 148. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 149. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 150. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 151. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 152. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 153. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 154. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 155. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 156. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 157. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. CANADA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 166. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 167. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 172. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 173. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. MEXICO GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 270. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 272. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 273. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 274. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 275. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2018-2024 (USD MILLION)
TABLE 276. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY PROKINETIC AGENTS, 2025-2030 (USD MILLION)
TABLE 277. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 278. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 279. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. GERMANY GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 288. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 289. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 290. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 291. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2024 (USD MILLION)
TABLE 292. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY ANTISPASMODICS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 294. FRANCE GASTROINTESTINAL MOTILITY DRUGS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gastrointestinal Motility Drugs Market report include:
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • Almirall, S.A.
  • AstraZeneca plc
  • Nektar Therapeutics, Inc.
  • Otsuka Pharmaceutical Co., Ltd.

Related Topics

Related Reports

Gastric Motility Disorder Drugs - Global Strategic Business Report - Product Image

Gastric Motility Disorder Drugs - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Diabetic Gastroparesis Treatment - Global Strategic Business Report - Product Image

Diabetic Gastroparesis Treatment - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From
Ineffective Esophageal Motility Treatment - Global Strategic Business Report - Product Image

Ineffective Esophageal Motility Treatment - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Ineffective Esophageal Motility Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Ineffective Esophageal Motility Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 280 Pages
  • Global
From
Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.